Atorvastatin Drug Interactions
Also known as: Lipitor, Caduet (with amlodipine), Liptruzet (with ezetimibe)
Atorvastatin (Lipitor) is the world's best-selling prescription drug and the most widely prescribed statin for lowering LDL ('bad') cholesterol and reducing the risk of heart attack, stroke, and cardiovascular death. It is used for both primary prevention (in people without established heart disease but with risk factors) and secondary prevention (in people who have already had a heart attack or stroke). Generic atorvastatin is available for as little as $4–$25 per month.Atorvastatin has 3 documented drug interactions in our database, including 0 contraindicated, 2 major, 1 moderate, and 0 minor interactions.
0
Contraindicated
2
Major
1
Moderate
0
Minor
Clarithromycin significantly increases atorvastatin exposure, raising the risk of myopathy and rhabdomyolysis.
Mechanism
Clarithromycin is a potent CYP3A4 inhibitor, reducing atorvastatin first-pass metabolism and increasing plasma levels up to 4-fold.
Clinical Management
Temporarily suspend atorvastatin during short courses of clarithromycin, or use a non-CYP3A4 statin (pravastatin, rosuvastatin).
Concomitant use of atorvastatin and amiodarone can increase the risk of myopathy and rhabdomyolysis due to elevated atorvastatin plasma concentrations. Patients may experience muscle pain, tenderness, or weakness, which can progress to severe muscle breakdown.
Mechanism
Amiodarone is a moderate inhibitor of CYP3A4, the primary enzyme responsible for atorvastatin metabolism. Inhibition of CYP3A4 by amiodarone leads to decreased clearance and increased systemic exposure of atorvastatin.
Clinical Management
If co-administration is necessary, limit atorvastatin dose to 20 mg daily and monitor patients closely for signs and symptoms of myopathy. Consider alternative statins with different metabolic pathways or alternative lipid-lowering therapies if muscle symptoms develop.
Concomitant use of atorvastatin and rosuvastatin is generally not recommended as it significantly increases the risk of dose-dependent statin-related adverse effects, particularly myopathy and rhabdomyolysis, without providing substantial additional lipid-lowering benefit. While both drugs lower cholesterol, combining them primarily elevates safety concerns.
Mechanism
Both atorvastatin and rosuvastatin are HMG-CoA reductase inhibitors, and their co-administration leads to an additive pharmacological effect, increasing systemic exposure to statins. This heightened exposure saturates metabolic pathways and increases the likelihood of dose-related toxicities, especially muscle-related adverse events.
Clinical Management
The co-administration of atorvastatin and rosuvastatin should generally be avoided. If a patient requires more intensive lipid lowering than a single statin can provide, alternative strategies such as increasing the dose of a single statin (within recommended limits), or adding a non-statin lipid-lowering agent (e.g., ezetimibe, PCSK9 inhibitor) should be considered. Monitor patients closely for muscle pain, tenderness, or weakness if this combination is inadvertently used.
For complete prescribing information:
View full Atorvastatin monograph →Already managing multiple medications?
Compare prices for all your prescriptions at 67,000+ pharmacies with one free RxGo search.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.